

Review

# On Commensalism of *Candida*

Jesus A. Romo  and Carol A. Kumamoto \*

Department of Molecular Biology and Microbiology, Tufts University, Boston, MA 02111, USA;  
Jesus.Romo@Tufts.edu

\* Correspondence: Carol.Kumamoto@Tufts.edu

Received: 30 November 2019; Accepted: 15 January 2020; Published: 17 January 2020



**Abstract:** *Candida* species are both opportunistic fungal pathogens and common members of the human mycobiome. Over the years, the main focus of the fungal field has been on understanding the pathogenic potential and disease manifestation of these organisms. Therefore, understanding of their commensal lifestyle, interactions with host epithelial barriers, and initial transition into pathogenesis is less developed. In this review, we will describe the current knowledge on the commensal lifestyle of these fungi, how they are able to adhere to and colonize host epithelial surfaces, compete with other members of the microbiota, and interact with the host immune response, as well as their transition into opportunistic pathogens by invading the gastrointestinal epithelium.

**Keywords:** *Candida*; gastrointestinal; colonization; mycobiome; commensalism; adhesion

---

## 1. Introduction

*Candida* species are opportunistic fungal pathogens and common members of the human mycobiome [1–3]. *Candida* species, primarily *Candida albicans*, are early colonizers acquired at or near birth primarily by physical contact [4,5]. These organisms are able to colonize the skin [6], as well as the gastrointestinal [7,8], and reproductive tracts of humans [9,10]. *C. albicans* is the most studied member of the genus with most of the research focused on its ability to cause disease [7,11–15]. Indeed, *C. albicans* is responsible for an unacceptably high number of symptomatic infections yearly that range from superficial (i.e., skin and mucous membranes) to invasive (i.e., internal organs) [7,16,17]. Most of these infections occur in immunocompromised individuals and originate from the gastrointestinal tract [18–23]. Therefore, it is crucial to narrow the gap in knowledge involving colonization, commensal lifestyle, and transition into a pathogenic state by *Candida* species. Interestingly, *Candida* species also appear to carry out functions that benefit the host. These include playing a role in the development of mucosal immune responses [24,25] and protection from *Clostridiooides difficile* infection in a murine model [26]. *Candida* species have clearly developed an intimate relationship with the host, which benefits the fungus and the host under certain circumstances. When this relationship is disturbed by antibiotic treatment or immune suppression however, the results can be catastrophic to the host. Below, we describe the current knowledge of *Candida* colonization and commensal lifestyle, with a brief discussion of invasion of epithelial barriers, primarily in the gastrointestinal tract.

## 2. *Candida* Gastrointestinal Colonization

As mentioned above, *Candida* species are acquired during or near birth [4,5] and become a significant part of the host mycobiome [1–3,27–30]. In order to cement their place in the host, they must be able to adhere to host epithelial cells and mucosal surfaces, resist and interact with host immune responses, and compete or cooperate with other members of the host microbiota. Additionally, *C. albicans* possesses the ability to undergo filamentation, a morphogenetic change from yeast to hyphae in response to an array of environmental signals, many of which are found in the host

gastrointestinal tract [31]. Hyphae are composed of elongated cells that do not separate after division and are the pathogenic form due to their ability to invade tissues. Hyphae are also required for proper biofilm formation of *C. albicans*, which allows it to endure environmental insults (e.g., antifungal treatment) [31–35]. Therefore, in order to successfully colonize the gastrointestinal tract, *C. albicans* must also successfully orchestrate morphogenetic transitions without harming the host and being eliminated by the subsequent immune response.

### 2.1. Adhesion

To date, there are no detailed studies of *Candida* species in the intestinal environment that strictly focus on commensalism. Moreover, knowledge of the role of adhesins during *Candida* colonization of the intestinal tract is minimal [36,37]. In this sub-section we will discuss the current knowledge of adhesins and their role in other niches that *Candida* species occupy and their potential role during intestinal colonization. The most studied adhesins utilized by *C. albicans* belong to the agglutinin-like sequence (ALS) gene family [38–40], which encode a group of GPI-anchored proteins with adhesive properties. These proteins have previously been shown to be present on the surface of the fungal cell wall [41,42], a structure composed mainly of chitin, glucans ( $\beta$ -1,3 and  $\beta$ -1,6), and mannans [43–48]. The ALS gene family consists of eight members (*ALS1*–*ALS7* and *ALS9*), with *ALS1* and *ALS3* being the most studied. Distinct members of the ALS family are expressed during the yeast and hyphal morphologies of *C. albicans* [49–51]. *ALS3* and the non-ALS adhesin Hyphal Wall Protein 1 (*HWP1*) are expressed mainly by hyphae [39,49,50,52–54]. Indeed, the distinct array of adhesins might be required for adaptation to distinct niches occupied by *Candida* species (i.e., oral, intestinal, and vaginal mucosal surfaces). Early studies have shown that *C. albicans* exhibits a greater ability to adhere to buccal epithelial cells (BECs) [55,56], vaginal epithelial cells (VECs) [57–59], uroepithelial cells [60], epithelium derived cell monolayers [61–63], and intestinal epithelial cells in vitro compared to other *Candida* species [64–66]. Although these studies did not directly address the role of specific adhesins, more recent studies have begun to elucidate specific roles [39,49,52,64,67–72]. Zakikhany et al., showed that the hyphal specific adhesin, *ALS3*, is highly upregulated during epithelial infection in vitro and that deletion of *ALS3* decreases this adhesion [73]. Similarly, deletion of *ALS2*, decreases adhesion [74,75]. Importantly, deletion of *ALS5*, *ALS6*, or *ALS7* resulted in an increase in adhesion highlighting the complex roles of adhesins [76]. Studies with *HWP1* have also demonstrated that this hyphal specific adhesin is highly expressed during colonization and infection of the oral epithelium and its deletion attenuates virulence in a murine model of oropharyngeal candidiasis [51,73,77]. The current knowledge of the role of adhesins in tissue culture systems and animal models is summarized in Table 1. These observations combined with the fact that *C. albicans* is able to very successfully colonize the gastrointestinal tract of humans [8,78–80], suggest that indeed distinct adhesins are required to successfully interact with the different environmental niches encountered by *C. albicans* and that multiple adhesins might be required for intestinal colonization.

**Table 1.** *C. albicans* adhesin profile in distinct niches.

Adhesin	Cell Culture		Human Samples and Animal Models (Gene Expression)		References
	Gene expression studies <sup>a</sup>	Adhesion assays <sup>b</sup>	Human samples <sup>a</sup>	Animal studies <sup>a</sup>	
<i>ALS1</i>	Reconstituted human vaginal epithelium (RHVE) from A431 cell line; Human Umbilical Vein Endothelial cells (HUVEC)	FaDu (pharynx carcinoma); Human Umbilical Vein Endothelial cells (HUVEC); Oral reconstituted human epithelium (TR146 cell line)		Vaginal candidiasis; Intestinal colonization (cecum);	[36,74,81–83]
<i>ALS2</i>	Reconstituted human vaginal epithelium (RHVE) from A431 cell line	Human Umbilical Vein Endothelial cells (HUVEC); Oral reconstituted human epithelium (TR146 cell line)		Vaginal candidiasis	[75,81,83]
<i>ALS3</i>	Pig liver infection (ex vivo); Oral reconstituted human epithelium (TR146 cell line); Reconstituted human vaginal epithelium (RHVE) from A431 cell line; Blood	FaDu (pharynx carcinoma); Human umbilical vein endothelial cells (HUVEC); Buccal epithelial cells (BEC); Buccal reconstituted human epithelium (RHE) model of oral candidiasis	Blood	Intraperitoneal infection model (liver); Vaginal candidiasis; Tail vein (blood infection model); Colonization model (stomach, cecum, and large Intestine)	[37,73,74,81,82,84–86]
<i>ALS4</i>		Human Umbilical Vein Endothelial cells (HUVEC);			[75]
<i>ALS5</i>		FaDu (pharynx carcinoma)			[82,83]
<i>ALS8</i>	Blood				[86]
<i>ALS9</i>	Reconstituted human vaginal epithelium (RHVE) from A431 cell line; Human umbilical vein endothelial cells (HUVEC)			Intraperitoneal infection model (liver); Vaginal candidiasis	[75,81]
<i>HWP1</i>	Pig liver infection (ex vivo); Oral reconstituted human epithelium (TR146 cell line); Blood, Enterocytes		Blood	Intraperitoneal infection model (liver); Blood, Colonization model (stomach, cecum, and large Intestine)	[37,73,81,84,86]
<i>HYR1</i>	Oral reconstituted human epithelium (TR146 cell line); Blood			Colonization model (stomach, cecum, and large Intestine)	[37,73,86]

Table lists <sup>a</sup> adhesins highly expressed in distinct model systems (e.g., cell culture vs. *in vivo*) as well as <sup>b</sup> adhesins required for binding to specific cell types in adhesion assays.

*C. albicans* morphogenetic states might play distinct roles during colonization of the gastrointestinal tract. *C. albicans* cells in the yeast state display decreased adhesion to enterocytes compared to oral epithelial cells *in vitro* [87]. Moreover, in these studies, most *C. albicans* cells underwent morphological transitions into hyphae, which enhanced their adhesive properties, as well as their virulence due to hyphal invasion into the host epithelial surfaces [50,87]. *C. albicans* invasion of epithelial surfaces occurs via two well characterized mechanisms, active penetration and endocytosis, both briefly described below. These *in vitro* studies suggest that *C. albicans* initial adhesion triggers filamentation and expression of virulence factors which lead to invasion of an epithelium. *C. albicans* must establish a relationship with the host in which none or minimal damage is caused in order to establish itself as a long-term colonizer [88]. When *C. albicans* is acquired early in life there could be some initial damage

due to filamentation, which could be overcome after the host immune response is able to mature and control pathogenic fungal populations.

*C. albicans* hyphal specific transcripts have been detected in several studies of murine models of gastrointestinal colonization [36,89]. The role of hyphae in intestinal commensalism however is still enigmatic since some studies have reported that yeast is the predominant morphology colonizing the gastrointestinal tract (~90%) [89,90]. More recently, Witchley and co-workers were able to show that yeast and hyphae morphologies co-occur throughout the gastrointestinal tract in a murine model. More importantly, they were able to identify a regulatory program involved in balancing commensal and pathogenic lifestyles of *C. albicans* [37]. The authors demonstrated that a master regulator of *C. albicans* filamentation, Ume6, reduced intestinal colonization fitness by activating the expression of the secreted aspartic proteinase 6 (Sap6) as well as the adhesin Hyr1, which triggered a pro-inflammatory response and subsequent clearance of the fungus by the host immune response. These results highlight the role of the environmental pressure coming from the host immune response and the ability of *C. albicans* populations to adapt to this stress.

To date, the majority of the studies involving adhesion and morphological states of *C. albicans* have been performed using in vitro models and primarily host niches other than the lower gastrointestinal tract. Clearly, the role of morphogenetic states along with specific adhesins expressed has not been fully addressed in the context of intestinal colonization and more studies are required in order to fully understand the role of these distinct morphologies, in addition to adhesins in interactions with host epithelial barriers.

In the last few decades, isolation of non-*Candida albicans* *Candida* (NCAC) species has significantly increased [5,13,91–94]. Less is known about NCAC as colonizers of the gastrointestinal tract. *C. glabrata* is another opportunistic pathogenic yeast and successful colonizer of the human gastrointestinal tract [1–3,28]. Although it is classified under the genus *Candida*, it is not a member of the CUG clade and is more closely related to *Saccharomyces cerevisiae* than to *C. albicans* [95]. *C. glabrata* is the second most commonly isolated *Candida* species from human samples in clinical laboratories behind *C. albicans* [91,96–101]. *C. glabrata* is unable to form true hyphae, but it is capable of adhering to host epithelial surfaces [102]. The adhesin repertoire utilized by *C. glabrata* consists of Epithelial Adhesin (Epa) and Epa-like proteins. Of this adhesin family, Epa1p has been shown to mediate adhesion to host epithelial cells (human laryngeal carcinoma, Hep2) [102] and macrophages [103]. Moreover, Epa6 and Epa7 have been shown to moderate adhesion to epithelial and endothelial cells [104,105]. In the case of the intestinal tract, a previous study identified adhesion properties of specific adhesins of *C. glabrata* expressed in *S. cerevisiae* to human epithelial colorectal adenocarcinoma cells (Caco2). The authors found that the adhesive properties of different adhesins ranged from significant to very weak adherence with Epa1, 6, and 7 displaying significant to moderate adhesion and Epa19-21 displaying weak adhesion [106]. *C. glabrata* colonization of the gastrointestinal tract is not well understood. Previous findings suggest that *C. glabrata* may require *C. albicans* for colonization and invasion of the oral cavity. Tati and co-workers demonstrated that *C. albicans* Als1 and Als3 were required for in vitro *C. glabrata* adhesion to *C. albicans* hyphae and to establish oropharyngeal candidiasis (OPC) in a murine model [107]. Moreover, *C. glabrata* cell wall protein genes EPA8, EPA19, AWP2, AWP7 and CAGL0F00181, were required for adhesion to *C. albicans*. These studies demonstrate that *C. glabrata* might be dependent on *C. albicans* for adhesion and invasion in the oral environment. Are these examples of fungal interactions that are important in the intestinal tract? In a recent interesting study, Gonia and co-workers demonstrated that another NCAC, *C. parapsilosis*, which is primarily a fungal pathogen of neonates, was able to protect premature intestinal epithelial cells (pIECs) from *C. albicans* invasion and damage [108]. More importantly, this protection was correlated with the adhesiveness of *C. parapsilosis* to *C. albicans* and to pIECs. These studies demonstrate that NCACs might play distinct roles during *C. albicans* colonization, invasion, and pathogenesis and further studies are required to begin to understand the complex ecosystem in which these fungi exist and interact with each other.

## 2.2. Specialized Morphotype for Survival in the Gastrointestinal Tract

More recently, *C. albicans* Gastrointestinally induced Transition (GUT) cells were identified by allowing wild type *C. albicans* to pass through the mammalian gastrointestinal tract [109]. These cell types underwent a phenotypic switch due to the expression of *WOR1*, a master switch transcription factor of white-opaque phenotypic switching in *C. albicans* [110,111]. White-opaque switching has been well characterized [112]. White and opaque cells have distinct gene expression of a large variety of processes [113,114]. Moreover, opaque cells have been identified as the mating competent phase [115,116]. Interestingly, GUT cells proved to be hypercompetitive and more fit in gastrointestinal colonization models as well as less virulent in a bloodstream murine model relative to white cells [109]. These observations indicate that yeast and hyphae are not the only morphogenetic states involved in colonization and commensalism of the host gastrointestinal tract. Moreover, GUT cells also express an array of transcripts optimized for lower gastrointestinal tract colonization. Among these, genes involved in the use of fatty acids and N-acetyl-glucosamine were upregulated, while genes involved in adhesion, glucose utilization, and iron uptake were downregulated. These patterns indicate that GUT cells are highly adapted to the nutrients available in the host lower gastrointestinal tract. Interestingly, GUT cells share similar metabolic characteristics with opaque cells, which are attenuated for commensalism [113]. These novel morphotypes require more investigation in order to truly understand their role in gastrointestinal colonization. What role do GUT cells play in *C. albicans* colonization and commensalism and do other *Candida* species have specialized cell types that promote gastrointestinal colonization?

## 2.3. Effects of *C. albicans* Colonization during Bacterial Infection

As mentioned earlier, most of the research on *Candida* species has focused on their pathogenic potential and there is a gap in knowledge about potential benefits provided to the host. One interesting example comes from murine studies performed by our group [26]. In these studies, antibiotic treated mice were either not colonized or pre-colonized with *C. albicans*. The animals were then challenged with the bacterial pathogen *Clostridioides difficile*. Surprisingly, the mice that were pre-colonized with *C. albicans* displayed a higher survival rate of a lethal *C. difficile* infection compared to the non-colonized mice. Moreover, one mechanism by which this protection was conferred was by the upregulation of *IL-17A* during *C. albicans* colonization.

Several groups have identified and characterized the interactions between *C. albicans* and *Pseudomonas aeruginosa* in distinct niches [117–119]. The interactions between these two organisms appear to be primarily antagonistic [117,120–122]. Previously, Lopez-Medina and co-workers used a neutropenic murine model to investigate the effect of *C. albicans* gastrointestinal colonization on *P. aeruginosa* pathogenesis [123]. Surprisingly, *C. albicans* specifically inhibited *P. aeruginosa* virulence without affecting the bacterium's colonization capabilities. The authors were able to determine that *C. albicans* inhibited *P. aeruginosa* virulence by suppressing gene expression of the siderophores pyochelin and pyoverdine. Moreover, the inhibition of these two siderophores by *C. albicans* increased mouse survival and decreased *P. aeruginosa* dissemination highlighting the importance of mycobiome in host health and disease. Thus, *C. albicans* colonization reduced disease caused by different bacterial pathogens.

Conversely, *C. tropicalis* has been shown to play a role in the exacerbation of Crohn's disease (CD) [124]. Hoarau and co-workers analyzed the micro- and mycobiota of patients with CD and their healthy relatives and found the bacteria *Serratia marcescens* and *Escherichia coli* elevated in CD patients. Interestingly, *C. tropicalis* was also elevated in CD patients and its abundance positively correlated with *S. marcescens* and *E. coli*, suggesting potential interactions between these three organisms. In subsequent experiments, the authors described an in vitro biofilm composed of all three organisms, which showed enhanced biomass, a distinct morphology of *C. tropicalis* in contrast to *C. tropicalis* only biofilms, and physical interactions between the organisms.

These examples indicate that related fungi may occupy distinct ecological roles in the host gastrointestinal tract. There is a need for further examination of the role of fungal commensals during host health and disease.

#### 2.4. Host Immune Response

The host is constantly surveying mucosal surfaces for pathogens and commensals such as *C. albicans*. Previous studies have demonstrated that the host is able to distinguish between yeast and filamentous *C. albicans* and therefore is able to identify commensalism or pathogenic infections [125]. Additionally, the host is able to sense increased fungal burdens, which could indicate an active infection, and respond [126]. For a review on specific receptors utilized by the host to sense fungi, see references [8,127]. Among these, Dectin-1 has been shown to be crucial for controlling fungal populations and both mice and humans either lacking or having a distinct polymorphism are highly prone to ulcerative colitis presumably triggered by fungal overgrowth [128]. Previous studies have suggested that *C. albicans* is able to select populations for colonization based on the immune status of the host [36,89]. In these studies, the authors demonstrated that *C. albicans* expression of the transcription factor *Efh1p* is upregulated in cells colonizing the murine gastrointestinal tract. Interestingly, expression of *EFH1* is associated with reduced colonization efficiency of the intestinal tract in animal models. In these models, cells lacking *EFH1* are able to successfully colonize the intestinal tract at higher levels than wild type, which displays intermediate colonization capabilities, while overexpression of *EFH1*, resulted in poor colonization of the intestinal tract. These studies suggest that *C. albicans* might be able to regulate population size in the host by modifying its gene expression, which could prevent strong immune responses by the host and subsequent antifungal effects. Another interesting adaptation of *C. albicans* in order to colonize the intestinal tract, is the expression of the transcription factor *EFG1*. This major regulator of *C. albicans* morphogenesis regulates the yeast to hyphal transition by responding to a variety of stimuli [84,129–133]. Previous studies demonstrated that expression of *EFG1* by *C. albicans* in the intestinal tract differed depending on the immune status of the host [134]. In contrast to the studies performed with *EFH1*, *C. albicans efg1*<sup>−</sup> null mutant proved to be hypersusceptible to the host immune response and therefore a poor colonizer. Both of these studies demonstrate that *C. albicans* gene expression is intimately connected to host immune status and this ability to accurately and effectively sense the host allows *C. albicans* to be a successful colonizer.

#### 2.5. Host Microbiota

In the host, *Candida* also has to compete for space and nutrients with other microorganisms in the ecosystem. Previous studies showed that anaerobes suppress *C. albicans* growth in the gastrointestinal tract of Syrian hamsters and that the removal of those anaerobes by treatment with penicillin allowed *C. albicans* to adhere, colonize, and disseminate from the gastrointestinal tract [135,136]. More recently, there is emerging evidence that members of the host microbiota affect *C. albicans* colonization of the gastrointestinal tract. One such study demonstrated that *Lactobacillus* species are antagonistic to *C. albicans* by producing indole-3-aldehyde (IAld), which stimulated IL-22 production resulting in antifungal activity [137]. Cruz and co-workers identified a EntV, a peptide secreted by *Enterococcus faecalis*, which was shown to inhibit *C. albicans* filamentation and virulence in a nematode infection model [138,139]. In these studies, the authors demonstrated that co-infection of a nematode with *E. faecalis* and *C. albicans* resulted in less pathology and less mortality than infection with either organism alone. The author hypothesizes that this phenomenon promotes a mutually beneficial association with the host, leading to a commensal lifestyle [140]. More recently, the same group demonstrated that EntV alone reduces invasion, inflammation, and fungal burden in a murine model of oropharyngeal candidiasis [139]. Lastly, Fan and co-workers were interested in factors that allow mice to exhibit *C. albicans* colonization resistance [141]. The authors identified a key role for commensal anaerobic bacteria, mainly clostridial Firmicutes and Bacteroidetes, in which the bacteria are able to activate the hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ). This activation led to the induction of the antimicrobial peptide LL-37 (CRAMP), which in

murine models, resulted in significant reduction of *C. albicans* intestinal colonization and a 50% decrease in mortality from invasive disease. These studies are outstanding examples of the complex interactions that *C. albicans* has to negotiate in order to colonize the host intestinal tract and highlight how dynamic and adaptable *C. albicans* must be in order to colonize distinct host niches.

Although *Candida* can establish an intimate and primarily benign relationship with the host, disturbances caused by antibiotics [21,142], damage of host epithelial barriers (e.g., due to bacterial toxins, trauma, or surgery) [143–145], or immune suppression [16] can lead to *Candida* overgrowth, invasion, and a transition to a pathogenic state.

### 3. Invasion

*C. albicans* invasion of epithelial surfaces leads to pathogenesis and is dependent on the yeast to hypha transition [146]. Interestingly, non-filamentous fungi such as *C. glabrata* have been shown to cross epithelial barriers in vitro [147]. Conversely, an efg1- null mutant displays a reduced ability to cross an epithelial Caco2 monolayer compared to the wild type and complemented strain [148]. These two observations highlight potentially distinct mechanisms of transepithelial migration and invasion. *C. albicans* invasion has been well characterized and two main mechanisms have emerged. These include epithelial-driven endocytosis [50,73,87,149] and *C. albicans* active penetration of epithelial surfaces by hyphae [12,87,150]. In vitro models have demonstrated that active penetration is the primary method of invading enterocytes during early stages of interaction [87]. Interestingly, recent studies have suggested that endocytosis occurs at a later time after *C. albicans* adheres to cells and this could be a potential mechanism for translocation through the gut barrier [151]. Both of these mechanisms have been extensively reviewed by Basmaciyan and co-workers [152]. Interestingly, Als3p has been reported to play a role in both endocytosis, active penetration, and overall invasion [146]. Results from these studies demonstrate that *C. albicans* as a commensal can interact with host epithelial barriers in distinct ways which allow it to colonize, invade, or both.

### 4. Concluding Remarks

During colonization, *C. albicans* interacts with its bacterial co-colonizers, the host epithelium and effectors of the host immune system. The outcome of these many interactions determines whether *C. albicans* will colonize as a benign commensal or become an invasive pathogen. Future work will reveal more details of these interactions, shedding light on the impact of *C. albicans* on the gastrointestinal tract ecosystem.

**Author Contributions:** Conceptualization, C.A.K. and J.A.R.; Original Draft Preparation, J.A.R.; Writing-Review and Editing, J.A.R. and C.A.K. All authors have read and agreed to the published version of the manuscript.

**Funding:** Research in our laboratory was supported by grant R01AI118898 (to C.A.K.) from the National Institutes of Health. J.A.R. is a Postdoctoral Scholar supported by the Tufts University MERGE-ID training grant (T32AI007329).

**Conflicts of Interest:** The authors declare no conflict of interest.

### References

1. Hallen-Adams, H.E.; Suhr, M.J. Fungi in the healthy human gastrointestinal tract. *Virulence* **2017**, *8*, 352–358. [[CrossRef](#)]
2. Mukherjee, P.K.; Sendid, B.; Hoarau, G.; Colombel, J.F.; Poulain, D.; Ghannoum, M.A. Mycobiota in gastrointestinal diseases. *Nat. Rev. Gastroenterol. Hepatol.* **2015**, *12*, 77–87. [[CrossRef](#)] [[PubMed](#)]
3. Nash, A.K.; Auchting, T.A.; Wong, M.C.; Smith, D.P.; Gesell, J.R.; Ross, M.C.; Stewart, C.J.; Metcalf, G.A.; Muzny, D.M.; Gibbs, R.A.; et al. The gut mycobiome of the Human Microbiome Project healthy cohort. *Microbiome* **2017**, *5*, 153. [[CrossRef](#)] [[PubMed](#)]
4. Reef, S.E.; Lasker, B.A.; Butcher, D.S.; McNeil, M.M.; Pruitt, R.; Keyserling, H.; Jarvis, W.R. Nonperinatal nosocomial transmission of *Candida albicans* in a neonatal intensive care unit: Prospective study. *J. Clin. Microbiol.* **1998**, *36*, 1255–1259. [[CrossRef](#)] [[PubMed](#)]

5. Kondori, N.; Nowrouzian, F.; Ajdari, M.; Hesselmar, B.; Saalman, R.; Wold, A.E.; Adlerberth, I. *Candida* species as commensal gut colonizers: A study of 133 longitudinally followed Swedish infants. *Med. Mycol.* **2019**. [[CrossRef](#)]
6. Kuhbacher, A.; Burger-Kentischer, A.; Rupp, S. Interaction of *Candida* Species with the Skin. *Microorganisms* **2017**, *5*, 32. [[CrossRef](#)] [[PubMed](#)]
7. Odds, F.C. *Candida* infections: An overview. *Crit. Rev. Microbiol.* **1987**, *15*, 1–5. [[CrossRef](#)] [[PubMed](#)]
8. Neville, B.A.; d'Enfert, C.; Bougnoux, M.E. *Candida albicans* commensalism in the gastrointestinal tract. *FEMS Yeast Res.* **2015**, *15*. [[CrossRef](#)] [[PubMed](#)]
9. Fidel, P.L., Jr. Vaginal candidiasis: Review and role of local mucosal immunity. *AIDS Patient Care STDS* **1998**, *12*, 359–366. [[CrossRef](#)]
10. Barousse, M.M.; Van Der Pol, B.J.; Fortenberry, D.; Orr, D.; Fidel, P.L., Jr. Vaginal yeast colonisation, prevalence of vaginitis, and associated local immunity in adolescents. *Sex. Transm. Infect.* **2004**, *80*, 48–53. [[CrossRef](#)]
11. Kojic, E.M.; Darouiche, R.O. *Candida* infections of medical devices. *Clin. Microbiol. Rev.* **2004**, *17*, 255–267. [[CrossRef](#)] [[PubMed](#)]
12. Naglik, J.R.; Challacombe, S.J.; Hube, B. *Candida albicans* secreted aspartyl proteinases in virulence and pathogenesis. *Microbiol. Mol. Biol. Rev.* **2003**, *67*, 400–428. [[CrossRef](#)] [[PubMed](#)]
13. Odds, F.C. Pathogenesis of *Candida* infections. *J. Am. Acad. Dermatol.* **1994**, *31*, S2–S5. [[CrossRef](#)]
14. Spellberg, B.; Ibrahim, A.S.; Edwards, J.E., Jr.; Filler, S.G. Mice with disseminated candidiasis die of progressive sepsis. *J. Infect. Dis.* **2005**, *192*, 336–343. [[CrossRef](#)] [[PubMed](#)]
15. Thompson, G.R., 3rd; Patel, P.K.; Kirkpatrick, W.R.; Westbrook, S.D.; Berg, D.; Erlandsen, J.; Redding, S.W.; Patterson, T.F. Oropharyngeal candidiasis in the era of antiretroviral therapy. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* **2010**, *109*, 488–495. [[CrossRef](#)] [[PubMed](#)]
16. Pfaller, M.A.; Diekema, D.J. Epidemiology of invasive candidiasis: A persistent public health problem. *Clin. Microbiol. Rev.* **2007**, *20*, 133–163. [[CrossRef](#)]
17. Brown, G.D.; Denning, D.W.; Gow, N.A.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: Human fungal infections. *Sci. Transl. Med.* **2012**, *4*, 165rv113. [[CrossRef](#)]
18. Nucci, M.; Anaissie, E. Revisiting the source of candidemia: Skin or gut? *Clin. Infect. Dis.* **2001**, *33*, 1959–1967. [[CrossRef](#)]
19. Miranda, L.N.; van der Heijden, I.M.; Costa, S.F.; Sousa, A.P.I.; Sienra, R.A.; Gobara, S.; Santos, C.R.; Lobo, R.D.; Pessoa, V.P., Jr.; Levin, A.S. *Candida* colonisation as a source for candidaemia. *J. Hosp. Infect.* **2009**, *72*, 9–16. [[CrossRef](#)]
20. Cole, G.T.; Lynn, K.T.; Seshan, K.R.; Pope, L.M. Gastrointestinal and systemic candidosis in immunocompromised mice. *J. Med. Vet. Mycol.* **1989**, *27*, 363–380. [[CrossRef](#)]
21. Ekenna, O.; Sherertz, R.J. Factors affecting colonization and dissemination of *Candida albicans* from the gastrointestinal tract of mice. *Infect. Immun.* **1987**, *55*, 1558–1563. [[CrossRef](#)] [[PubMed](#)]
22. Mellado, E.; Cuenca-Estrella, M.; Regadera, J.; Gonzalez, M.; Diaz-Guerra, T.M.; Rodriguez-Tudela, J.L. Sustained gastrointestinal colonization and systemic dissemination by *Candida albicans*, *Candida tropicalis* and *Candida parapsilosis* in adult mice. *Diagn. Microbiol. Infect. Dis.* **2000**, *38*, 21–28. [[CrossRef](#)]
23. Koh, A.Y.; Kohler, J.R.; Coggshall, K.T.; Van Rooijen, N.; Pier, G.B. Mucosal damage and neutropenia are required for *Candida albicans* dissemination. *PLoS Pathog.* **2008**, *4*, e35. [[CrossRef](#)] [[PubMed](#)]
24. Atarashi, K.; Tanoue, T.; Ando, M.; Kamada, N.; Nagano, Y.; Narushima, S.; Suda, W.; Imaoka, A.; Setoyama, H.; Nagamori, T.; et al. Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells. *Cell* **2015**, *163*, 367–380. [[CrossRef](#)] [[PubMed](#)]
25. Ifrim, D.C.; Quintin, J.; Meerstein-Kessel, L.; Plantinga, T.S.; Joosten, L.A.; van der Meer, J.W.; van de Veerdonk, F.L.; Netea, M.G. Defective trained immunity in patients with STAT-1-dependent chronic mucocutaneous candidiasis. *Clin. Exp. Immunol.* **2015**, *181*, 434–440. [[CrossRef](#)] [[PubMed](#)]
26. Markey, L.; Shaban, L.; Green, E.R.; Lemon, K.P.; Mecsas, J.; Kumamoto, C.A. Pre-colonization with the commensal fungus *Candida albicans* reduces murine susceptibility to *Clostridium difficile* infection. *Gut. Microbes* **2018**, *9*, 497–509. [[CrossRef](#)]
27. Witherden, E.A.; Shoae, S.; Hall, R.A.; Moyes, D.L. The Human Mucosal Mycobiome and Fungal Community Interactions. *J. Fungi.* **2017**, *3*, 56. [[CrossRef](#)]
28. Huffnagle, G.B.; Noverr, M.C. The emerging world of the fungal microbiome. *Trends Microbiol.* **2013**, *21*, 334–341. [[CrossRef](#)]

29. Huseyin, C.E.; Rubio, R.C.; O’Sullivan, O.; Cotter, P.D.; Scanlan, P.D. The Fungal Frontier: A Comparative Analysis of Methods Used in the Study of the Human Gut Mycobiome. *Front. Microbiol.* **2017**, *8*, 1432. [[CrossRef](#)]
30. Oever, J.T.; Netea, M.G. The bacteriome-mycobiome interaction and antifungal host defense. *Eur. J. Immunol.* **2014**, *44*, 3182–3191. [[CrossRef](#)]
31. Sudbery, P.E. Growth of *Candida albicans* hyphae. *Nat. Rev. Microbiol.* **2011**, *9*, 737–748. [[CrossRef](#)] [[PubMed](#)]
32. Sudbery, P.; Gow, N.; Berman, J. The distinct morphogenic states of *Candida albicans*. *Trends Microbiol.* **2004**, *12*, 317–324. [[CrossRef](#)] [[PubMed](#)]
33. Sudbery, P.E. The germ tubes of *Candida albicans* hyphae and pseudohyphae show different patterns of septin ring localization. *Mol. Microbiol.* **2001**, *41*, 19–31. [[CrossRef](#)] [[PubMed](#)]
34. Bonhomme, J.; d’Enfert, C. *Candida albicans* biofilms: Building a heterogeneous, drug-tolerant environment. *Curr. Opin. Microbiol.* **2013**, *16*, 398–403. [[CrossRef](#)]
35. Chandra, J.; Kuhn, D.M.; Mukherjee, P.K.; Hoyer, L.L.; McCormick, T.; Ghannoum, M.A. Biofilm Formation by the Fungal Pathogen *Candida albicans*: Development, Architecture, and Drug Resistance. *J. Bacteriol.* **2001**, *183*, 5385–5394. [[CrossRef](#)]
36. Rosenbach, A.; Dignard, D.; Pierce, J.V.; Whiteway, M.; Kumamoto, C.A. Adaptations of *Candida albicans* for growth in the mammalian intestinal tract. *Eukaryot. Cell* **2010**, *9*, 1075–1086. [[CrossRef](#)]
37. Witchley, J.N.; Penumetcha, P.; Abon, N.V.; Woolford, C.A.; Mitchell, A.P.; Noble, S.M. *Candida albicans* Morphogenesis Programs Control the Balance between Gut Commensalism and Invasive Infection. *Cell Host Microbe* **2019**, *25*, 432–443. [[CrossRef](#)]
38. Hoyer, L.L. The ALS gene family of *Candida albicans*. *Trends Microbiol.* **2001**, *9*, 176–180. [[CrossRef](#)]
39. Hoyer, L.L.; Payne, T.L.; Bell, M.; Myers, A.M.; Scherer, S. *Candida albicans* ALS3 and insights into the nature of the ALS gene family. *Curr. Genet.* **1998**, *33*, 451–459. [[CrossRef](#)]
40. Hoyer, L.L.; Scherer, S.; Shatzman, A.R.; Livi, G.P. *Candida albicans* ALS1: Domains related to a *Saccharomyces cerevisiae* sexual agglutinin separated by a repeating motif. *Mol. Microbiol.* **1995**, *15*, 39–54. [[CrossRef](#)]
41. Hoyer, L.L.; Clevenger, J.; Hecht, J.E.; Ehrhart, E.J.; Poulet, F.M. Detection of Als proteins on the cell wall of *Candida albicans* in murine tissues. *Infect. Immun.* **1999**, *67*, 4251–4255. [[CrossRef](#)] [[PubMed](#)]
42. Hoyer, L.L.; Payne, T.L.; Hecht, J.E. Identification of *Candida albicans* ALS2 and ALS4 and localization of als proteins to the fungal cell surface. *J. Bacteriol.* **1998**, *180*, 5334–5343. [[CrossRef](#)] [[PubMed](#)]
43. Arana, D.M.; Prieto, D.; Roman, E.; Nombela, C.; Alonso-Monge, R.; Pla, J. The role of the cell wall in fungal pathogenesis. *Microb. Biotechnol.* **2009**, *2*, 308–320. [[CrossRef](#)] [[PubMed](#)]
44. Cabib, E.; Bowers, B.; Sburlati, A.; Silverman, S.J. Fungal cell wall synthesis: The construction of a biological structure. *Microbiol. Sci.* **1988**, *5*, 370–375. [[PubMed](#)]
45. Fradin, C.; Bernardes, E.S.; Jouault, T. *Candida albicans* phospholipomannan: A sweet spot for controlling host response/inflammation. *Semin. Immunopathol.* **2015**, *37*, 123–130. [[CrossRef](#)]
46. Free, S.J. Fungal cell wall organization and biosynthesis. *Adv. Genet.* **2013**, *81*, 33–82. [[CrossRef](#)]
47. Gow, N.A.R.; Latge, J.P.; Munro, C.A. The Fungal Cell Wall: Structure, Biosynthesis, and Function. *Microbiol. Spectr.* **2017**, *5*. [[CrossRef](#)] [[PubMed](#)]
48. Hubbard, M.J.; Sullivan, P.A.; Shepherd, M.G. Morphological studies of N-acetylglucosamine induced germ tube formation by *Candida albicans*. *Can. J. Microbiol.* **1985**, *31*, 696–701. [[CrossRef](#)]
49. Almeida, R.S.; Brunke, S.; Albrecht, A.; Thewes, S.; Laue, M.; Edwards, J.E.; Filler, S.G.; Hube, B. the hyphal-associated adhesin and invasin Als3 of *Candida albicans* mediates iron acquisition from host ferritin. *PLoS Pathog.* **2008**, *4*, e1000217. [[CrossRef](#)]
50. Phan, Q.T.; Myers, C.L.; Fu, Y.; Sheppard, D.C.; Yeaman, M.R.; Welch, W.H.; Ibrahim, A.S.; Edwards, J.E., Jr.; Filler, S.G. Als3 is a *Candida albicans* invasin that binds to cadherins and induces endocytosis by host cells. *PLoS Biol.* **2007**, *5*, e64. [[CrossRef](#)]
51. Sundstrom, P.; Balish, E.; Allen, C.M. Essential role of the *Candida albicans* transglutaminase substrate, hyphal wall protein 1, in lethal oroesophageal candidiasis in immunodeficient mice. *J. Infect. Dis.* **2002**, *185*, 521–530. [[CrossRef](#)] [[PubMed](#)]
52. Ene, I.V.; Bennett, R.J. Hwp1 and related adhesins contribute to both mating and biofilm formation in *Candida albicans*. *Eukaryot. Cell* **2009**, *8*, 1909–1913. [[CrossRef](#)] [[PubMed](#)]
53. Staab, J.F.; Bradway, S.D.; Fidel, P.L.; Sundstrom, P. Adhesive and mammalian transglutaminase substrate properties of *Candida albicans* Hwp1. *Science* **1999**, *283*, 1535–1538. [[CrossRef](#)] [[PubMed](#)]

54. Argimon, S.; Wishart, J.A.; Leng, R.; Macaskill, S.; Mavor, A.; Alexandris, T.; Nicholls, S.; Knight, A.W.; Enjalbert, B.; Walmsley, R.; et al. Developmental regulation of an adhesin gene during cellular morphogenesis in the fungal pathogen *Candida albicans*. *Eukaryot. Cell* **2007**, *6*, 682–692. [CrossRef]
55. King, R.D.; Lee, J.C.; Morris, A.L. Adherence of *Candida albicans* and other *Candida* species to mucosal epithelial cells. *Infect. Immun.* **1980**, *27*, 667–674. [CrossRef] [PubMed]
56. Sandin, R.L.; Rogers, A.L.; Patterson, R.J.; Beneke, E.S. Evidence for mannose-mediated adherence of *Candida albicans* to human buccal cells in vitro. *Infect. Immun.* **1982**, *35*, 79–85. [CrossRef]
57. Lee, J.C.; King, R.D. Characterization of *Candida albicans* adherence to human vaginal epithelial cells in vitro. *Infect. Immun.* **1983**, *41*, 1024–1030. [CrossRef]
58. Segal, E.; Lehrer, N.; Ofek, I. Adherence of *Candida albicans* to human vaginal epithelial cells: Inhibition by amino sugars. *Exp. Cell Biol.* **1982**, *50*, 13–17. [CrossRef]
59. Sobel, J.D.; Myers, P.G.; Kaye, D.; Levison, M.E. Adherence of *Candida albicans* to human vaginal and buccal epithelial cells. *J. Infect. Dis.* **1981**, *143*, 76–82. [CrossRef]
60. Centeno, A.; Davis, C.P.; Cohen, M.S.; Warren, M.M. Modulation of *Candida albicans* attachment to human epithelial cells by bacteria and carbohydrates. *Infect. Immun.* **1983**, *39*, 1354–1360. [CrossRef]
61. Farrell, S.M.; Hawkins, D.F.; Ryder, T.A. Scanning electron microscope study of *Candida albicans* invasion of cultured human cervical epithelial cells. *Sabouraudia* **1983**, *21*, 251–254. [CrossRef] [PubMed]
62. Samaranayake, L.P.; MacFarlane, T.W. The adhesion of the yeast *Candida albicans* to epithelial cells of human origin in vitro. *Arch. Oral Biol.* **1981**, *26*, 815–820. [CrossRef]
63. Samaranayake, L.P.; MacFarlane, T.W. Factors affecting the in-vitro adherence of the fungal oral pathogen *Candida albicans* to epithelial cells of human origin. *Arch. Oral Biol.* **1982**, *27*, 869–873. [CrossRef]
64. Modrzenska, B.; Kurnatowski, P. Adherence of *Candida* sp. to host tissues and cells as one of its pathogenicity features. *Ann. Parasitol.* **2015**, *61*, 3–9. [PubMed]
65. Falgier, C.; Kegley, S.; Podgorski, H.; Heisel, T.; Storey, K.; Bendel, C.M.; Gale, C.A. *Candida* species differ in their interactions with immature human gastrointestinal epithelial cells. *Pediatr. Res.* **2011**, *69*, 384–389. [CrossRef]
66. Sandin, R.L.; Rogers, A.L. Inhibition of adherence of *Candida albicans* to human epithelial cells. *Mycopathologia* **1982**, *77*, 23–26. [CrossRef]
67. Calderone, R.A.; Fonzi, W.A. Virulence factors of *Candida albicans*. *Trends Microbiol.* **2001**, *9*, 327–335. [CrossRef]
68. Hoyer, L.L.; Green, C.B.; Oh, S.H.; Zhao, X. Discovering the secrets of the *Candida albicans* agglutinin-like sequence (ALS) gene family—A sticky pursuit. *Med. Mycol.* **2008**, *46*, 1–15. [CrossRef]
69. Kumamoto, C.A.; Vinces, M.D. Contributions of hyphae and hypha-co-regulated genes to *Candida albicans* virulence. *Cell. Microbiol.* **2005**, *7*, 1546–1554. [CrossRef]
70. Nobile, C.J.; Andes, D.R.; Nett, J.E.; Smith, F.J.; Yue, F.; Phan, Q.T.; Edwards, J.E.; Filler, S.G.; Mitchell, A.P. Critical role of Bcr1-dependent adhesins in *C. albicans* biofilm formation in vitro and in vivo. *PLoS Pathog.* **2006**, *2*, e63. [CrossRef]
71. Cleary, I.A.; Reinhard, S.M.; Miller, C.L.; Murdoch, C.; Thornhill, M.H.; Lazzell, A.L.; Monteagudo, C.; Thomas, D.P.; Saville, S.P. *Candida albicans* adhesin Als3p is dispensable for virulence in the mouse model of disseminated candidiasis. *Microbiology* **2011**, *157*, 1806–1815. [CrossRef] [PubMed]
72. Martin, R.; Albrecht-Eckardt, D.; Brunke, S.; Hube, B.; Hunniger, K.; Kurzai, O. A core filamentation response network in *Candida albicans* is restricted to eight genes. *PLoS ONE* **2013**, *8*, e58613. [CrossRef] [PubMed]
73. Zakikhany, K.; Naglik, J.R.; Schmidt-Westhausen, A.; Holland, G.; Schaller, M.; Hube, B. In vivo transcript profiling of *Candida albicans* identifies a gene essential for interepithelial dissemination. *Cell. Microbiol.* **2007**, *9*, 2938–2954. [CrossRef] [PubMed]
74. Zhao, X.; Oh, S.H.; Cheng, G.; Green, C.B.; Nuessen, J.A.; Yeater, K.; Leng, R.P.; Brown, A.J.; Hoyer, L.L. ALS3 and ALS8 represent a single locus that encodes a *Candida albicans* adhesin; functional comparisons between Als3p and Als1p. *Microbiology* **2004**, *150*, 2415–2428. [CrossRef] [PubMed]
75. Zhao, X.; Oh, S.H.; Yeater, K.M.; Hoyer, L.L. Analysis of the *Candida albicans* Als2p and Als4p adhesins suggests the potential for compensatory function within the Als family. *Microbiology* **2005**, *151*, 1619–1630. [CrossRef] [PubMed]
76. Zhao, X.; Oh, S.H.; Hoyer, L.L. Deletion of *ALS5*, *ALS6* or *ALS7* increases adhesion of *Candida albicans* to human vascular endothelial and buccal epithelial cells. *Med. Mycol.* **2007**, *45*, 429–434. [CrossRef]

77. Naglik, J.R.; Fostira, F.; Ruprai, J.; Staab, J.F.; Challacombe, S.J.; Sundstrom, P. *Candida albicans* HWP1 gene expression and host antibody responses in colonization and disease. *J. Med Microbiol.* **2006**, *55*, 1323–1327. [CrossRef]
78. Perez, J.C.; Kumamoto, C.A.; Johnson, A.D. *Candida albicans* commensalism and pathogenicity are intertwined traits directed by a tightly knit transcriptional regulatory circuit. *PLoS Biol.* **2013**, *11*, e1001510. [CrossRef]
79. Pierce, J.V.; Dignard, D.; Whiteway, M.; Kumamoto, C.A. Normal adaptation of *Candida albicans* to the murine gastrointestinal tract requires Efg1p-dependent regulation of metabolic and host defense genes. *Eukaryot. Cell* **2013**, *12*, 37–49. [CrossRef]
80. Shao, T.Y.; Ang, W.X.G.; Jiang, T.T.; Huang, F.S.; Andersen, H.; Kinder, J.M.; Pham, G.; Burg, A.R.; Ruff, B.; Gonzalez, T.; et al. Commensal *Candida albicans* Positively Calibrates Systemic Th17 Immunological Responses. *Cell Host Microbe* **2019**, *25*, 404–417. [CrossRef]
81. Cheng, G.; Wozniak, K.; Wallig, M.A.; Fidel, P.L., Jr.; Trupin, S.R.; Hoyer, L.L. Comparison between *Candida albicans* agglutinin-like sequence gene expression patterns in human clinical specimens and models of vaginal candidiasis. *Infect. Immun.* **2005**, *73*, 1656–1663. [CrossRef] [PubMed]
82. Sheppard, D.C.; Yeaman, M.R.; Welch, W.H.; Phan, Q.T.; Fu, Y.; Ibrahim, A.S.; Filler, S.G.; Zhang, M.; Waring, A.J.; Edwards, J.E., Jr. Functional and structural diversity in the Als protein family of *Candida albicans*. *J. Biol. Chem.* **2004**, *279*, 30480–30489. [CrossRef]
83. Alberti-Segui, C.; Morales, A.J.; Xing, H.; Kessler, M.M.; Willins, D.A.; Weinstock, K.G.; Cottarel, G.; Fechtel, K.; Rogers, B. Identification of potential cell-surface proteins in *Candida albicans* and investigation of the role of a putative cell-surface glycosidase in adhesion and virulence. *Yeast* **2004**, *21*, 285–302. [CrossRef]
84. Sascha, T.; Marianne, K.; Hyunsook, P.; Martin, S.; Filler, S.G.; Bernhard, H. In vivo and ex vivo comparative transcriptional profiling of invasive and non-invasive *Candida albicans* isolates identifies genes associated with tissue invasion. *Mol. Microbiol.* **2007**, *63*, 1606–1628. [CrossRef]
85. Wilson, D.; Thewes, S.; Zakikhany, K.; Fradin, C.; Albrecht, A.; Almeida, R.; Brunke, S.; Grosse, K.; Martin, R.; Mayer, F.; et al. Identifying infection-associated genes of *Candida albicans* in the postgenomic era. *FEMS Yeast Res.* **2009**, *9*, 688–700. [CrossRef] [PubMed]
86. Fradin, C.; Kretschmar, M.; Nichterlein, T.; Gaillardin, C.; d'Enfert, C.; Hube, B. Stage-specific gene expression of *Candida albicans* in human blood. *Mol. Microbiol.* **2003**, *47*, 1523–1543. [CrossRef] [PubMed]
87. Dalle, F.; Wachtler, B.; L'Ollivier, C.; Holland, G.; Bannert, N.; Wilson, D.; Labruere, C.; Bonnin, A.; Hube, B. Cellular interactions of *Candida albicans* with human oral epithelial cells and enterocytes. *Cell. Microbiol.* **2010**, *12*, 248–271. [CrossRef] [PubMed]
88. Casadevall, A.; Pirofski, L.A. Host-pathogen interactions: Basic concepts of microbial commensalism, colonization, infection, and disease. *Infect. Immun.* **2000**, *68*, 6511–6518. [CrossRef]
89. White, S.J.; Rosenbach, A.; Lephart, P.; Nguyen, D.; Benjamin, A.; Tzipori, S.; Whiteway, M.; Mecsas, J.; Kumamoto, C.A. Self-regulation of *Candida albicans* population size during GI colonization. *PLoS Pathog.* **2007**, *3*, e184. [CrossRef]
90. Vautier, S.; Drummond, R.A.; Chen, K.; Murray, G.I.; Kadosh, D.; Brown, A.J.; Gow, N.A.; MacCallum, D.M.; Kolls, J.K.; Brown, G.D. *Candida albicans* colonization and dissemination from the murine gastrointestinal tract: The influence of morphology and Th17 immunity. *Cell. Microbiol.* **2015**, *17*, 445–450. [CrossRef]
91. Fidel, P.L., Jr.; Vazquez, J.A.; Sobel, J.D. *Candida glabrata*: Review of epidemiology, pathogenesis, and clinical disease with comparison to *C. albicans*. *Clin. Microbiol. Rev.* **1999**, *12*, 80–96. [CrossRef] [PubMed]
92. Gilfillan, G.D.; Sullivan, D.J.; Haynes, K.; Parkinson, T.; Coleman, D.C.; Gow, N.A. *Candida dubliniensis*: Phylogeny and putative virulence factors. *Microbiology* **1998**, *144 Pt 4*, 829–838. [CrossRef]
93. Martinez, M.; Lopez-Ribot, J.L.; Kirkpatrick, W.R.; Coco, B.J.; Bachmann, S.P.; Patterson, T.F. Replacement of *Candida albicans* with *C. dubliniensis* in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. *J. Clin. Microbiol.* **2002**, *40*, 3135–3139. [CrossRef] [PubMed]
94. Pfaller, M.A.; Diekema, D.J.; Gibbs, D.L.; Newell, V.A.; Ellis, D.; Tullio, V.; Rodloff, A.; Fu, W.; Ling, T.A.; Global Antifungal Surveillance, G. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of *Candida* Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. *J. Clin. Microbiol.* **2010**, *48*, 1366–1377. [CrossRef] [PubMed]
95. Butler, G.; Rasmussen, M.D.; Lin, M.F.; Santos, M.A.; Sakthikumar, S.; Munro, C.A.; Rheinbay, E.; Grabherr, M.; Forche, A.; Reedy, J.L.; et al. Evolution of pathogenicity and sexual reproduction in eight *Candida* genomes. *Nature* **2009**, *459*, 657–662. [CrossRef]

96. Bassetti, M.; Righi, E.; Costa, A.; Fasce, R.; Molinari, M.P.; Rosso, R.; Pallavicini, F.B.; Viscoli, C. Epidemiological trends in nosocomial candidemia in intensive care. *BMC Infect. Dis.* **2006**, *6*, 21. [[CrossRef](#)]
97. Colombo, A.L.; Guimaraes, T.; Silva, L.R.; de Almeida Monfardini, L.P.; Cunha, A.K.; Rady, P.; Alves, T.; Rosas, R.C. Prospective observational study of candidemia in São Paulo, Brazil: Incidence rate, epidemiology, and predictors of mortality. *Infect. Control Hosp. Epidemiol.* **2007**, *28*, 570–576. [[CrossRef](#)]
98. Chakrabarti, A.; Chatterjee, S.S.; Rao, K.L.; Zameer, M.M.; Shivaprakash, M.R.; Singh, S.; Singh, R.; Varma, S.C. Recent experience with fungaemia: Change in species distribution and azole resistance. *Scand. J. Infect. Dis.* **2009**, *41*, 275–284. [[CrossRef](#)]
99. Hasan, F.; Xess, I.; Wang, X.; Jain, N.; Fries, B.C. Biofilm formation in clinical *Candida* isolates and its association with virulence. *Microbes Infect.* **2009**, *11*, 753–761. [[CrossRef](#)]
100. Fenn, J.P.; Billetdeaux, E.; Segal, H.; Skodack-Jones, L.; Padilla, P.E.; Bale, M.; Carroll, K. Comparison of four methodologies for rapid and cost-effective identification of *Candida glabrata*. *J. Clin. Microbiol.* **1999**, *37*, 3387–3389. [[CrossRef](#)]
101. Peltroche-Llacsahuanga, H.; Schnitzler, N.; Lutticken, R.; Haase, G. Rapid identification of *Candida glabrata* by using a dipstick to detect trehalase-generated glucose. *J. Clin. Microbiol.* **1999**, *37*, 202–205. [[CrossRef](#)] [[PubMed](#)]
102. Cormack, B.P.; Ghori, N.; Falkow, S. An adhesin of the yeast pathogen *Candida glabrata* mediating adherence to human epithelial cells. *Science* **1999**, *285*, 578–582. [[CrossRef](#)] [[PubMed](#)]
103. Kuhn, D.M.; Vyas, V.K. The *Candida glabrata* adhesin Epa1p causes adhesion, phagocytosis, and cytokine secretion by innate immune cells. *FEMS Yeast Res.* **2012**, *12*, 398–414. [[CrossRef](#)] [[PubMed](#)]
104. Domergue, R.; Castano, I.; De Las Penas, A.; Zupancic, M.; Lockatell, V.; Hebel, J.R.; Johnson, D.; Cormack, B.P. Nicotinic acid limitation regulates silencing of *Candida* adhesins during UTI. *Science* **2005**, *308*, 866–870. [[CrossRef](#)] [[PubMed](#)]
105. Zupancic, M.L.; Frieman, M.; Smith, D.; Alvarez, R.A.; Cummings, R.D.; Cormack, B.P. Glycan microarray analysis of *Candida glabrata* adhesin ligand specificity. *Mol. Microbiol.* **2008**, *68*, 547–559. [[CrossRef](#)] [[PubMed](#)]
106. Diderrick, R.; Kock, M.; Maestre-Reyna, M.; Keller, P.; Steuber, H.; Rupp, S.; Essen, L.O.; Mosch, H.U. Structural Hot Spots Determine Functional Diversity of the *Candida glabrata* Epithelial Adhesin Family. *J. Biol. Chem.* **2015**, *290*, 19597–19613. [[CrossRef](#)]
107. Tati, S.; Davidow, P.; McCall, A.; Hwang-Wong, E.; Rojas, I.G.; Cormack, B.; Edgerton, M. *Candida glabrata* Binding to *Candida albicans* Hyphae Enables Its Development in Oropharyngeal Candidiasis. *PLoS Pathog.* **2016**, *12*, e1005522. [[CrossRef](#)]
108. Gonia, S.; Archambault, L.; Shevik, M.; Altendahl, M.; Fellows, E.; Bliss, J.M.; Wheeler, R.T.; Gale, C.A. *Candida parapsilosis* Protects Premature Intestinal Epithelial Cells from Invasion and Damage by *Candida albicans*. *Front. Pediatr.* **2017**, *5*, 54. [[CrossRef](#)]
109. Pande, K.; Chen, C.; Noble, S.M. Passage through the mammalian gut triggers a phenotypic switch that promotes *Candida albicans* commensalism. *Nat. Genet.* **2013**, *45*, 1088–1091. [[CrossRef](#)]
110. Huang, G.; Wang, H.; Chou, S.; Nie, X.; Chen, J.; Liu, H. Bistable expression of WOR1, a master regulator of white-opaque switching in *Candida albicans*. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 12813–12818. [[CrossRef](#)]
111. Srikantha, T.; Borneman, A.R.; Daniels, K.J.; Pujol, C.; Wu, W.; Seringhaus, M.R.; Gerstein, M.; Yi, S.; Snyder, M.; Soll, D.R. TOS9 regulates white-opaque switching in *Candida albicans*. *Eukaryot. Cell* **2006**, *5*, 1674–1687. [[CrossRef](#)]
112. Slutsky, B.; Staebell, M.; Anderson, J.; Risen, L.; Pfaller, M.; Soll, D.R. “White-opaque transition”: A second high-frequency switching system in *Candida albicans*. *J. Bacteriol.* **1987**, *169*, 189–197. [[CrossRef](#)] [[PubMed](#)]
113. Lan, C.Y.; Newport, G.; Murillo, L.A.; Jones, T.; Scherer, S.; Davis, R.W.; Agabian, N. Metabolic specialization associated with phenotypic switching in *Candida albicans*. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 14907–14912. [[CrossRef](#)] [[PubMed](#)]
114. Tuch, B.B.; Mitrovich, Q.M.; Homann, O.R.; Hernday, A.D.; Monighetti, C.K.; De La Vega, F.M.; Johnson, A.D. The transcriptomes of two heritable cell types illuminate the circuit governing their differentiation. *PLoS Genet.* **2010**, *6*, e1001070. [[CrossRef](#)] [[PubMed](#)]
115. Lockhart, S.R.; Pujol, C.; Daniels, K.J.; Miller, M.G.; Johnson, A.D.; Pfaller, M.A.; Soll, D.R. In *Candida albicans*, white-opaque switchers are homozygous for mating type. *Genetics* **2002**, *162*, 737–745. [[PubMed](#)]
116. Miller, M.G.; Johnson, A.D. White-opaque switching in *Candida albicans* is controlled by mating-type locus homeodomain proteins and allows efficient mating. *Cell* **2002**, *110*, 293–302. [[CrossRef](#)]

117. Hogan, D.A.; Kolter, R. *Pseudomonas-Candida* interactions: An ecological role for virulence factors. *Science* **2002**, *296*, 2229–2232. [CrossRef] [PubMed]
118. Hogan, D.A.; Vik, A.; Kolter, R. A *Pseudomonas aeruginosa* quorum-sensing molecule influences *Candida albicans* morphology. *Mol. Microbiol.* **2004**, *54*, 1212–1223. [CrossRef] [PubMed]
119. Morales, D.K.; Hogan, D.A. *Candida albicans* interactions with bacteria in the context of human health and disease. *PLoS Pathog.* **2010**, *6*, e1000886. [CrossRef]
120. Bandara, H.M.; Yau, J.Y.; Watt, R.M.; Jin, L.J.; Samaranayake, L.P. *Pseudomonas aeruginosa* inhibits in-vitro *Candida* biofilm development. *BMC Microbiol.* **2010**, *10*, 125. [CrossRef]
121. Holcombe, L.J.; McAlester, G.; Munro, C.A.; Enjalbert, B.; Brown, A.J.P.; Gow, N.A.R.; Ding, C.; Butler, G.; O’Gara, F.; Morrissey, J.P. *Pseudomonas aeruginosa* secreted factors impair biofilm development in *Candida albicans*. *Microbiology* **2010**, *156*, 1476–1486. [CrossRef] [PubMed]
122. Bandara, H.M.; BP, K.C.; Watt, R.M.; Jin, L.J.; Samaranayake, L.P. *Pseudomonas aeruginosa* lipopolysaccharide inhibits *Candida albicans* hyphae formation and alters gene expression during biofilm development. *Mol. Oral Microbiol.* **2013**, *28*, 54–69. [CrossRef] [PubMed]
123. Lopez-Medina, E.; Fan, D.; Coughlin, L.A.; Ho, E.X.; Lamont, I.L.; Reimann, C.; Hooper, L.V.; Koh, A.Y. *Candida albicans* Inhibits *Pseudomonas aeruginosa* Virulence through Suppression of Pyochelin and Pyoverdine Biosynthesis. *PLoS Pathog.* **2015**, *11*, e1005129. [CrossRef] [PubMed]
124. Hoarau, G.; Mukherjee, P.K.; Gower-Rousseau, C.; Hager, C.; Chandra, J.; Retuerto, M.A.; Neut, C.; Vermeire, S.; Clemente, J.; Colombel, J.F.; et al. Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn’s Disease. *mBio* **2016**, *7*. [CrossRef] [PubMed]
125. Naglik, J.R.; Moyes, D.L.; Wachtler, B.; Hube, B. *Candida albicans* interactions with epithelial cells and mucosal immunity. *Microbes Infect.* **2011**, *13*, 963–976. [CrossRef] [PubMed]
126. Moyes, D.L.; Shen, C.; Murciano, C.; Runglall, M.; Richardson, J.P.; Arno, M.; Aldecoa-Otalora, E.; Naglik, J.R. Protection against epithelial damage during *Candida albicans* infection is mediated by PI3K/Akt and mammalian target of rapamycin signaling. *J. Infect. Dis.* **2014**, *209*, 1816–1826. [CrossRef] [PubMed]
127. Plato, A.; Hardison, S.E.; Brown, G.D. Pattern recognition receptors in antifungal immunity. *Semin. Immunopathol.* **2015**, *37*, 97–106. [CrossRef]
128. Iliev, I.D.; Funari, V.A.; Taylor, K.D.; Nguyen, Q.; Reyes, C.N.; Strom, S.P.; Brown, J.; Becker, C.A.; Fleshner, P.R.; Dubinsky, M.; et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. *Science* **2012**, *336*, 1314–1317. [CrossRef]
129. Hameed, S.; Prasad, T.; Banerjee, D.; Chandra, A.; Mukhopadhyay, C.K.; Goswami, S.K.; Lattif, A.A.; Chandra, J.; Mukherjee, P.K.; Ghannoum, M.A.; et al. Iron deprivation induces *EFG1*-mediated hyphal development in *Candida albicans* without affecting biofilm formation. *FEMS Yeast Res.* **2008**, *8*, 744–755. [CrossRef]
130. Doedt, T.; Krishnamurthy, S.; Bockmuhl, D.P.; Tebarth, B.; Stempel, C.; Russell, C.L.; Brown, A.J.; Ernst, J.F. APSES proteins regulate morphogenesis and metabolism in *Candida albicans*. *Mol. Biol. Cell* **2004**, *15*, 3167–3180. [CrossRef]
131. Nantel, A.; Dignard, D.; Bachewich, C.; Harcus, D.; Marcil, A.; Bouin, A.P.; Sensen, C.W.; Hogues, H.; van het Hoog, M.; Gordon, P.; et al. Transcription profiling of *Candida albicans* cells undergoing the yeast-to-hyphal transition. *Mol. Biol. Cell* **2002**, *13*, 3452–3465. [CrossRef] [PubMed]
132. Setiadi, E.R.; Doedt, T.; Cottier, F.; Noffz, C.; Ernst, J.F. Transcriptional response of *Candida albicans* to hypoxia: Linkage of oxygen sensing and Efg1p-regulatory networks. *J. Mol. Biol.* **2006**, *361*, 399–411. [CrossRef] [PubMed]
133. Walker, L.A.; MacCallum, D.M.; Bertram, G.; Gow, N.A.; Odds, F.C.; Brown, A.J. Genome-wide analysis of *Candida albicans* gene expression patterns during infection of the mammalian kidney. *Fungal Genet. Biol.* **2009**, *46*, 210–219. [CrossRef] [PubMed]
134. Pierce, J.V.; Kumamoto, C.A. Variation in *Candida albicans* *EFG1* expression enables host-dependent changes in colonizing fungal populations. *MBio* **2012**, *3*, e00117-12. [CrossRef]
135. Kennedy, M.J. Regulation of *Candida albicans* populations in the gastrointestinal tract: Mechanisms and significance in GI and systemic candidiasis. *Curr. Top. Med. Mycol.* **1989**, *3*, 315–402.
136. Kennedy, M.J.; Volz, P.A. Ecology of *Candida albicans* gut colonization: Inhibition of *Candida* adhesion, colonization, and dissemination from the gastrointestinal tract by bacterial antagonism. *Infect. Immun.* **1985**, *49*, 654–663. [CrossRef]

137. Zelante, T.; Iannitti, R.G.; Cunha, C.; De Luca, A.; Giovannini, G.; Pieraccini, G.; Zecchi, R.; D’Angelo, C.; Massi-Benedetti, C.; Fallarino, F.; et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity* **2013**, *39*, 372–385. [CrossRef]
138. Cruz, M.R.; Graham, C.E.; Gagliano, B.C.; Lorenz, M.C.; Garsin, D.A. *Enterococcus faecalis* inhibits hyphal morphogenesis and virulence of *Candida albicans*. *Infect. Immun.* **2013**, *81*, 189–200. [CrossRef]
139. Graham, C.E.; Cruz, M.R.; Garsin, D.A.; Lorenz, M.C. *Enterococcus faecalis* bacteriocin EntV inhibits hyphal morphogenesis, biofilm formation, and virulence of *Candida albicans*. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 4507–4512. [CrossRef]
140. Garsin, D.A.; Lorenz, M.C. *Candida albicans* and *Enterococcus faecalis* in the gut: Synergy in commensalism? *Gut Microbes* **2013**, *4*, 409–415. [CrossRef]
141. Fan, D.; Coughlin, L.A.; Neubauer, M.M.; Kim, J.; Kim, M.S.; Zhan, X.; Simms-Waldrip, T.R.; Xie, Y.; Hooper, L.V.; Koh, A.Y. Activation of HIF-1alpha and LL-37 by commensal bacteria inhibits *Candida albicans* colonization. *Nat. Med.* **2015**, *21*, 808–814. [CrossRef] [PubMed]
142. Samonis, G.; Gikas, A.; Anaissie, E.J.; Vrenzos, G.; Maraki, S.; Tselenitis, Y.; Bodey, G.P. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. *Antimicrob. Agents Chemother.* **1993**, *37*, 51–53. [CrossRef] [PubMed]
143. Pasqualotto, A.C.; Nedel, W.L.; Machado, T.S.; Severo, L.C. Risk factors and outcome for nosocomial breakthrough candidaemia. *J. Infect.* **2006**, *52*, 216–222. [CrossRef] [PubMed]
144. Ott, S.J.; Kuhbacher, T.; Musfeldt, M.; Rosenstiel, P.; Hellmig, S.; Rehman, A.; Drews, O.; Weichert, W.; Timmis, K.N.; Schreiber, S. Fungi and inflammatory bowel diseases: Alterations of composition and diversity. *Scand. J. Gastroenterol.* **2008**, *43*, 831–841. [CrossRef] [PubMed]
145. Sokol, H.; Leducq, V.; Aschard, H.; Pham, H.P.; Jegou, S.; Landman, C.; Cohen, D.; Liguori, G.; Bourrier, A.; Nion-Larmurier, I.; et al. Fungal microbiota dysbiosis in IBD. *Gut* **2017**, *66*, 1039–1048. [CrossRef] [PubMed]
146. Wachtler, B.; Wilson, D.; Haedicke, K.; Dalle, F.; Hube, B. From attachment to damage: Defined genes of *Candida albicans* mediate adhesion, invasion and damage during interaction with oral epithelial cells. *PLoS ONE* **2011**, *6*, e17046. [CrossRef]
147. Perez-Torrado, R.; Querol, A. *Saccharomyces cerevisiae* show low levels of traversal across human endothelial barrier in vitro. *F1000Res* **2017**, *6*, 944. [CrossRef]
148. Weide, M.R.; Ernst, J.F. Caco-2 monolayer as a model for transepithelial migration of the fungal pathogen *Candida albicans*. *Mycoses* **1999**, *42* (Suppl. 2), 61–67. [CrossRef]
149. Park, H.; Myers, C.L.; Sheppard, D.C.; Phan, Q.T.; Sanchez, A.A.; E. Edwards, J.; Filler, S.G. Role of the fungal Ras-protein kinase A pathway in governing epithelial cell interactions during oropharyngeal candidiasis. *Cell. Microbiol.* **2005**, *7*, 499–510. [CrossRef]
150. Felk, A.; Kretschmar, M.; Albrecht, A.; Schaller, M.; Beinhauer, S.; Nichterlein, T.; Sanglard, D.; Korting, H.C.; Schafer, W.; Hube, B. *Candida albicans* hyphal formation and the expression of the Efg1-regulated proteinases Sap4 to Sap6 are required for the invasion of parenchymal organs. *Infect. Immun.* **2002**, *70*, 3689–3700. [CrossRef]
151. Goyer, M.; Loiselet, A.; Bon, F.; L’Ollivier, C.; Laue, M.; Holland, G.; Bonnin, A.; Dalle, F. Intestinal Cell Tight Junctions Limit Invasion of *Candida albicans* through Active Penetration and Endocytosis in the Early Stages of the Interaction of the Fungus with the Intestinal Barrier. *PLoS ONE* **2016**, *11*, e0149159. [CrossRef] [PubMed]
152. Basmaciyan, L.; Bon, F.; Paradis, T.; Lapaquette, P.; Dalle, F. *Candida Albicans* Interactions With The Host: Crossing The Intestinal Epithelial Barrier. *Tissue Barriers* **2019**, *7*, 1612661. [CrossRef] [PubMed]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).